Thyroid hormones alterations in acute-on-chronic liver failure: a focus on liver transplantation and survival outcomes [0.03%]
急性-on-慢性肝功能衰竭的甲状腺激素变化：重点探讨肝脏移植和生存结果的影响
Artur Kośnik,Dominika Kurpiewska,Maciej Janik et al.
Artur Kośnik et al.
"Double diabetes?" Diagnostic and therapeutic challenges in patient with established type 1 diabetes mellitus, developing features of type 2 diabetes mellitus [0.03%]
“双糖尿病？”1型糖尿病患者出现2型糖尿病特征的诊断和治疗挑战
Kamil Możdżeń,Jakub P Pośpiech,Agnieszka J Murawska et al.
Kamil Możdżeń et al.
Lipomatous hypertrophy of the interatrial septum in a woman with sick sinus syndrome [0.03%]
患窦房综合征女性患者的房间隔脂肪瘤样增生
Barbara Zdzierak,Iwona Ciszek,Bernadeta Chyrchel et al.
Barbara Zdzierak et al.
Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful? [0.03%]
使用胰高血糖素样肽-1受体激动剂后出现视力障碍：这会有害吗？
Maria Cecilia Bahit,Michael Gibson,Martyna Kuleta et al.
Maria Cecilia Bahit et al.
Antithrombotic therapy in patients with inherited bleeding disorders: practical considerations [0.03%]
血友病患者抗凝治疗的注意事项
Jerzy Windyga,Riitta Lassila
Jerzy Windyga
For decades hemophilia and allied bleeding disorders caused by inherited deficiency of clotting factors were considered conditions protecting against thromboembolism (TE). This opinion was coined over 60 years ago, when average life expecta...
Effectiveness of coronary sinus reducer implantation in routine clinical practice. 12-month outcomes [0.03%]
冠状窦固定器植入的临床效果：12个月随访结果
Szymon Włodarczak,Piotr Rola,Artur Jastrzębski et al.
Szymon Włodarczak et al.
Introduction: Refractory angina (RA) due to the lack of therapeutic options still remains a significant challenge. Coronary Sinus Reducer (CSR) has been recently introduced in the field of therapy of this advance form of ...
A placebo-adjusted effect of the initial eGFR decline following SGLT-2 inhibitor initia-tion: a systematic review and meta-analysis [0.03%]
钠葡萄糖协同转运蛋白-2抑制剂初始应用后肾小球滤过率下降的安慰剂对照效应：系统评价和meta分析
Szymon Urban,Jan Biegus,Mikołaj Błaziak et al.
Szymon Urban et al.
Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are pivotal in managing heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus. While their beneficial impact is well-established, ...
Giovanni Landoni,Antonio Pisano
Giovanni Landoni
Breaking the weight loss paradox: from weight reduction to cardiovascular benefit in obesity treatment [0.03%]
打破减肥悖论：从减轻体重到心血管获益的肥胖治疗转型
Grzegorz Gajos
Grzegorz Gajos
Obesity is a growing global epidemic and a major risk factor for cardiovascular disease. However, previous weight loss interventions have largely failed to demonstrate consistent cardiovascular benefits. While lifestyle modifications remain...